How Changing the Definition of “Sick” — and Medicalizing Aging — Created $Millions in Profit for "Big Pharma"
- Rex Ballard
- 10 minutes ago
- 4 min read
A recent discussion on X pointed out an uncomfortable pattern: the diagnostic thresholds for common conditions keep shifting, instantly turning large numbers of previously healthy people into patients—and reliable customers for the pharmaceutical industry. Hypertension, prediabetes, and diabetes were the examples cited. Those cases are well documented. They are also part of a larger process that has increasingly treated normal aging itself as a collection of medical deficiencies requiring lifelong drug treatment.
Lowering the Bar: Hypertension, Diabetes, Cholesterol, and Osteoporosis
For decades, high blood pressure was generally defined as 160/95 mm Hg or 140/90 mm Hg. In 2017 the American College of Cardiology and American Heart Association lowered the threshold to 130/80. The share of U.S. adults classified as hypertensive jumped from roughly 32 percent to about 46 percent—an estimated 30 million additional people. Earlier guidelines had already created the category of “prehypertension.”
A similar story unfolded with blood sugar. In 1979 the diabetes threshold stood at a fasting plasma glucose of 140 mg/dL. In 1997 it dropped to 126. Prediabetes cutoffs were later lowered still further. Today roughly one in three American adults meets criteria for prediabetes or diabetes.
Cholesterol followed the same trajectory. Thresholds fell from total cholesterol above 240 mg/dL to 200, with ever-lower LDL targets. One change alone reclassified an estimated 42 million Americans.
Osteoporosis shifted from a diagnosis based mainly on actual fractures to a bone-density T-score of –2.5 or lower, complete with an intermediate “osteopenia” category. Large percentages of postmenopausal women were suddenly labeled diseased or pre-diseased. Shortly afterward, drugs such as Fosamax became major commercial successes.
In each case, many of the expert panels that rewrote the definitions included substantial numbers of members with financial ties to the companies that sell the resulting medications.
Turning Aging into a "Treatable Condition"
The most expansive version of this pattern targets aging itself. Bone density, blood pressure, cholesterol, testosterone, and muscle mass all decline with age. Previous generations largely accepted these changes as expected. Guideline writers and marketers have increasingly reframed them as medical problems that require pharmaceutical correction.
Osteoporosis is the clearest example. Once viewed as a natural consequence of aging, bone loss was formalized as a disease category through T-scores. The global market for osteoporosis drugs already runs in the $10–17 billion range and continues to expand as populations age and more expensive agents enter use.
Normal age-related declines in testosterone were rebranded as “Low T” or andropause. Direct-to-consumer advertising and permissive prescribing guidelines drove U.S. testosterone sales from a few hundred million dollars in the early 2000s to roughly $2 billion within a decade. Menopause, a natural transition, was long marketed as an estrogen-deficiency disease requiring hormone therapy both for symptoms and for purported protection against the diseases of aging. The related market is estimated at $10–25 billion.
Uniform numerical thresholds for blood pressure, lipids, and glucose are applied to people in their 70s and 80s much as they are to younger adults. The predictable result is high rates of statin, antihypertensive, and diabetes-drug use among the elderly—often stacked on top of one another.
Aging is universal. Chronic conditions of aging generate chronic prescriptions. Expanding the definition of what counts as abnormal increases the addressable market without requiring a new molecule.
Proven treatments for significant disease have helped people live longer. The industrial-scale medicalization of normal aging—turning ordinary age-related changes into lifelong multi-drug regimens—has not clearly translated into longer lives and carries documented harms. Quality of life, functional independence, and careful weighing of absolute benefit versus burden matter at least as much as adding years on paper.
Polypharmacy and the Revenue Engine
The downstream effect is visible in the numbers. More than half of U.S. adults aged 65 and older are prescribed five or more medications. Roughly one in six Medicare Part D beneficiaries take eight or more drugs at the same time. This polypharmacy drives higher spending, adverse drug events, falls, cognitive side effects, and hospitalizations—costs that themselves generate further medical activity.
These are not niche products. Statins, blood-pressure drugs, diabetes medications, osteoporosis therapies, and testosterone rank among the highest-volume and highest-revenue categories in the industry. The same companies that help shape the definitions also spend hundreds of millions of dollars each year on federal lobbying—consistently ranking as the top industry spender—to protect pricing power and market access for the very products whose use expands when the goalposts move.
How the System Works
Guideline panels for hypertension, cholesterol, diabetes, and related conditions have repeatedly included high percentages of members with financial relationships to manufacturers. Industry funding of medical societies and continuing education further shapes the intellectual environment in which “pre-disease” categories and lower thresholds become accepted as normal science.
This pattern does not require a conspiracy. Continuous risk gradients exist, and some high-risk older patients clearly benefit from treatment. The problem is the systematic tendency: definitions expand more readily than they contract, absolute benefits for milder or purely age-related cases are often modest, and the commercial upside is large and concentrated.
What It Means Locally
Shasta County’s older population is not exempt. National guidelines flow directly into local clinics and Medicare practices. The result is a steady conversion of ordinary aging into multi-drug regimens. Lifestyle factors—adequate protein intake, resistance training, walking, sleep, and avoiding ultra-processed foods—remain the highest-leverage interventions for most of these age-related changes. They simply generate no recurring revenue stream comparable to a daily pill.
Readers should approach new or lowered diagnostic cutoffs, especially those applied to older adults, with skepticism. Ask for absolute risk reduction figures in people of similar age and health status. Distinguish true pathology from the natural variability of aging. A laboratory number is not destiny—particularly when the number itself has been adjusted by committees with financial ties to the companies that profit from treating it.
Lifestyle and personal responsibility remain the most powerful tools available. They do not require a prescription, and they do not expand anyone’s market.
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional medical diagnosis, treatment, or advice. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or before making any decisions about your health, medications, or treatment plan.
